#1 Clinical Trials Search in Europe

Metoprolol Succinate

Metoprolol Succinate is a medication widely used to manage heart-related issues. The following article discusses various clinical trials concerning Metoprolol Succinate, aiming to provide insights into its efficacy and safety. These trials explore various dosages, treatment combinations, and patient conditions to better understand the drug’s impact on health outcomes.

Table of Contents

What is Metoprolol Succinate?

Metoprolol Succinate is a medication that belongs to a class of drugs called beta-blockers. It’s also known by brand names such as TOPROL-XL and Betaloc ZOK[1][2]. This medication is widely used in the treatment of various cardiovascular conditions and is available in extended-release tablet form.

Conditions Treated by Metoprolol Succinate

Metoprolol Succinate is used to treat several cardiovascular conditions, including:

  • High Blood Pressure (Hypertension): It helps lower blood pressure by reducing the workload on the heart[3].
  • Heart Failure: It’s used in patients with reduced ejection fraction, which means the heart’s ability to pump blood is decreased[6].
  • Angina Pectoris: This is chest pain caused by reduced blood flow to the heart. Metoprolol Succinate can help manage this condition[4].
  • Post-COVID-19 Syndrome: Some studies are exploring its use in managing symptoms like tachycardia (rapid heart rate) and dyspnea (shortness of breath) in patients recovering from COVID-19[5].

How Metoprolol Succinate Works

Metoprolol Succinate works by blocking the effects of the hormone epinephrine, also known as adrenaline. This action:

  • Slows down the heart rate
  • Reduces the force of heart contractions
  • Decreases blood pressure
  • Improves blood flow through the body

By doing this, it reduces the workload on the heart, making it easier for the heart to pump blood effectively[3][4].

Dosage Forms and Administration

Metoprolol Succinate is available as an extended-release tablet. The dosage can vary depending on the condition being treated and the individual patient’s needs. Some common dosages include:

  • 50 mg once daily[2]
  • 95 mg to 190 mg once daily[4]
  • 200 mg once daily[1]

It’s important to note that your doctor will determine the right dosage for you based on your specific condition and how you respond to the medication.

Effectiveness of Metoprolol Succinate

Several studies have shown the effectiveness of Metoprolol Succinate in treating various cardiovascular conditions:

  • In patients with heart failure, it has been shown to improve heart function and reduce mortality rates[6].
  • For patients with stable angina, it can help control heart rate and reduce the frequency of angina attacks[4].
  • In hypertension management, it effectively lowers blood pressure when used alone or in combination with other medications[3].

Potential Side Effects

Like all medications, Metoprolol Succinate can cause side effects. Some potential side effects include:

  • Fatigue or weakness
  • Dizziness
  • Slow heart rate (bradycardia)
  • Cold hands and feet
  • Gastrointestinal issues like nausea or constipation

It’s important to discuss any side effects with your healthcare provider. They can adjust your dosage or consider alternative treatments if necessary[4][5].

Ongoing Research and Future Prospects

Research on Metoprolol Succinate is ongoing, with several studies exploring its potential benefits in various conditions:

  • Its use in managing symptoms of post-COVID-19 syndrome, particularly tachycardia and shortness of breath[5].
  • Comparative studies with other beta-blockers like carvedilol in heart failure treatment[6].
  • Its potential role in preventing complications in patients with liver cirrhosis[7].

These ongoing studies may provide more insights into the broader applications and benefits of Metoprolol Succinate in the future.

Trial ID Title Phase Primary Outcome Conditions Studied
NCT01673997 Bioequivalence Study of Metoprolol Succinate ER Tablets, 200 mg Phase 1 Area under curve (AUC) Healthy
NCT01694797 Bioequivalence Study for Metoprolol Succinate ER Tablets 50 mg Phase 1 Area under curve (AUC) Healthy
NCT00642096 Factorial Study of Metoprolol Succinate TOPROL-XL (324A) Phase 3 Change in diastolic blood pressure Hypertension
NCT01213173 Evaluation of Succinate Metoprolol on Heart Rate in Stable Angina Patients Phase 4 Impact on 24-hr Average Heart Rate Angina Pectoris

FAQ

  • What is Metoprolol Succinate? Metoprolol Succinate is a type of beta-blocker medication used to treat high blood pressure, angina (chest pain), and heart failure. It helps to lower the heart rate, blood pressure, and strain on the heart.
  • What is a bioequivalence study? A bioequivalence study compares two pharmaceutical products to determine if they perform similarly in the body, ensuring that a generic product is as effective as a branded one.
  • What does fasting conditions mean in a clinical trial? Fasting conditions refer to not having eaten for a certain period before taking medication, which helps researchers understand how the drug works without the influence of food.
  • What is the significance of the 'Area under the curve (AUC)'? AUC measures the drug's exposure in the body over time. It helps determine how much and how long a drug stays effective in the system.
  • How does Metoprolol Succinate help with angina? Metoprolol Succinate reduces the heart's workload and oxygen demand, which can lower the frequency and intensity of angina attacks.

Ongoing Clinical Trials on Metoprolol Succinate

  • Study of stopping heart failure medications in patients with non-ischemic cardiomyopathy who responded very well to cardiac resynchronization therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Comparison of ivabradine, atenolol, and metoprolol for heart rate control in patients with ischemic heart disease before cardiac CT examination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study of flecainide alone or with beta-blockers or calcium channel blockers and quinidine for treating ventricular arrhythmias in patients with Andersen-Tawil syndrome and MEPPC

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Optimizing Treatment for Chronic Heart Failure with Reduced Ejection Fraction Using Nebivolol and a Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Czechia

  • Comparing Carvedilol and Metoprolol Succinate for Treating Heart Failure with Reduced Ejection Fraction in Patients at Heart Failure Clinics

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study on Preventing Heart Disease in Diabetes Patients Using Eprosartan Mesilate and Drug Combination

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Austria Spain

  • Study on the Effects of Metoprolol, Prasugrel, and Carbasalate Calcium in Patients with Spontaneous Coronary Artery Dissection

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Bioequivalence: A comparison between two drugs to see if they work the same way in the body.
  • Angina: Chest pain or discomfort that occurs when the heart doesn't get enough blood and oxygen.
  • Hypertension: A medical condition where the blood pressure in the arteries is persistently elevated.
  • Phase IV: Post-marketing studies to delineate additional information including the drug's risks, benefits, and optimal use.
  • Crossover Study: A type of clinical trial where participants receive a sequence of different treatments, allowing researchers to compare the effects directly.

References

  1. https://clinicaltrials.gov/study/NCT01673997
  2. https://clinicaltrials.gov/study/NCT01694797
  3. https://clinicaltrials.gov/study/NCT00642096
  4. https://clinicaltrials.gov/study/NCT01213173
  5. https://clinicaltrials.gov/study/NCT05096884
  6. https://clinicaltrials.eu/trial/comparing-carvedilol-and-metoprolol-succinate-for-treating-heart-failure-with-reduced-ejection-fraction-in-patients-at-heart-failure-clinics/
  7. https://clinicaltrials.gov/study/NCT01676285